Rhinomed partners to promote Turbine device


By Dylan Bushell-Embling
Thursday, 10 July, 2014


Rhinomed partners to promote Turbine device

Melbourne-based breathing technology company Rhinomed (ASX:RNO) will team up with an international fitness chain to promote its Turbine breathing technology.

Rhinomed will partner with the Fitness First gym and health club network in Australia to show off Turbine throughout the month of July.

As part of the collaboration, Turbine will be provided to fitness class instructors at 40 health club locations in Australia and displayed on 600 digital panels and TVs in around 70 facilities. The technology will also be showcased in the new edition of Fitness First Magazine.

The promotion has been designed to coincide with the Tour de France cycling competition, as cyclists are a key target market for the product.

In May, Rhinomed appointed Australian former Tour de France green jersey winner Baden Cooke as a Turbine brand ambassador in Europe. Cooke is using this year’s event to promote the technology to European cyclists.

Turbine is a nasal clip designed to minimise shortness of breath resulting from strenuous exercise using Rhinomed’s BreatheAssist technology. It pushes the nostrils open to allow for an average of 38% more air intake.

Rhinomed separately revealed that it recorded revenue from Turbine sales of $201,000 for the June quarter, up from $9000 the quarter before. Turbine launched in January.

The company attributed the sales growth to the product’s increasing penetration within the Australian cycling community and with wholesalers.

Besides the fitness segment, Rhinomed is also developing applications for its BreatheAssist technology in the sleep and snoring as well as drug delivery segments.

Rhinomed aims to launch a product designed to address night-time nasal congestion later this year. The company has meanwhile accelerated its Sumatriptan drug delivery program, appointing IDT Australia (ASX:IDT) to assist with the development of the Sumatriptan delivery device.

Rhinomed (ASX:RNO) shares were trading unchanged at $0.046 as of around noon on Thursday.

Related Articles

Bright nights may increase risk of death, Alzheimer's

Avoiding night light and seeking daylight may lead to reduction in disease burden, especially...

COVID-19 infection increases risk of heart attack and stroke

COVID-19 infection may increase the risk of heart attack, stroke and death from any cause for up...

A bout of COVID could protect you from a severe case of flu

Recovery from COVID appears to have a protective effect against the worst effects of the flu,...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd